Several new anticoagulants have entered the clinical arena or are under clinical
development. These drugs include indirect (fondaparinux) and direct oral factor Xa inhibitors …

The prescription of new oral anticoagulants is on the rise. As opposed to vitamin K
antagonists and heparins the new agents have single targets in the coagulation cascade …

Abstract Oral Factor Xa (FXa) inhibitors, a growing class of direct-acting anticoagulants, are
frequently used to prevent stroke and systemic embolism in patients with atrial fibrillation …

Abstract Background Direct factor Xa inhibitors have demonstrated compelling anticoagulant
efficacy and/or safety profiles across multiple diverse patient populations. A specific antidote …

The use of direct oral anticoagulants over traditional warfarin has increased in the United
States over the past 10 years because of advantages such as ease of use, predictable …

Over the past several years a new era for patients requiring anticoagulation has arrived. The
approval of new target specific oral anticoagulants offers practitioners several advantages …

Purpose To describe the pharmacologic agents and strategies used for urgent reversal of
warfarin and the target-specific oral anticoagulants dabigatran, rivaroxaban, and apixaban …

The most important adverse effect of antithrombotic treatment is the occurrence of bleeding.
In the case of severe bleeding in a patient who uses anticoagulant agents or when a patient …

Essentials• There remains clinical concern regarding the optimal management of direct oral
(DOAC) anticoagulant effect for emergencies such as bleeding or urgent …

Oral anticoagulants, old and new, are effective therapies for prevention and treatment of
venous thromboembolism and reduction of stroke risk in patients with atrial fibrillation …